Miraculins Inc. (TSX VENTURE:MOM), a medical diagnostic company

focused on acquiring, developing and commercializing diagnostic tests

and risk assessment technologies for unmet clinical needs, and Pear

Healthcare Solutions Inc., a leading provider of in-pharmacy health

screening and education services, today announce an agreement that

will see the PreVu@ Non-Invasive Skin Cholesterol Point of Care (POC)

Test distributed to the Canadian retail pharmacy market.

Pear Healthcare Solutions will distribute the PreVu POC Test to

Canadian retail pharmacies and work with pharmacy partners to

establish coronary artery disease (CAD) screening programs using skin

cholesterol and other known risk factors for implementation in

pharmacy settings across the country. The PreVu POC Test contains two

components: the PreVu Handheld Spectrophotometer, which is used to

both guide the operator through the test and take the skin cholesterol

reading; and the Reagent Test Kit, comprised of reagent solution and

test consumables. The short-term focus of Pear Healthcare Solutions

will be to establish pilot testing locations for the testing programs.

Once a successful implementation model has been established, Pear will

be responsible for a broad national roll-out of the program at

pharmacy locations Canada-wide.

"Pear has pioneered a number of highly successful market introductions

and in-store risk assessment clinics at Canadian pharmacies," said

Mark Doyle, Vice President of Sales and Marketing for Pear Healthcare

Solutions Inc. "Based on our track record of past successes

implementing health assessment programs using innovative products, we

know that there is tremendous interest in public screening programs

utilizing novel, non-invasive technologies like PreVu.

"Leveraging our existing relationships with Canada's largest retail

pharmacy chains, we are confident in a strong response from our

customers to the introduction of the PreVu Non-Invasive Skin

Cholesterol Test," continued Doyle.

"Despite the risk information available to patients and caregivers

today, there are over 70,000 heart attacks in Canada each year,

resulting in over 16,000 deaths," stated Paul Moreau, Vice President,

Sales & Marketing for Miraculins Inc. "In less than five minutes, and

without discomfort, drawing blood or requiring fasting, PreVu can

identify Canadians with hidden, high levels of risk of CAD and impress

upon them as never before the importance of seeing their healthcare

professionals for a full evaluation of their heart disease risk

factors towards prevention of that first critical event.

"We are very pleased to be working with Pear Healthcare Solutions to

make the PreVu POC Test available to Canadian communities and families

through retail pharmacies," Moreau added. "Our agreement with Pear is

consistent with our stated strategy to partner with market leaders,

and as further evidenced by our recent partnership announcement with

The Stevens Company to reach the medical/clinical channel, we continue

to leverage relationships with exceptional companies towards making

PreVu available to at-risk Canadians who need it most."

About the PreVu Non-Invasive Skin Cholesterol Test

Skin cholesterol is the cholesterol that has been deposited and

diffused into tissue, as opposed to free circulating in the

bloodstream, and has been shown in clinical trials to be strongly

associated with significant CAD as measured by treadmill stress

testing, coronary angiography, coronary calcium and carotid artery

thickening. The PreVu POC Test is completely painless, non-invasive,

involves no blood draw or needles, requires no overnight fasting and

involves no handling of potentially hazardous biomaterials. It has

been developed to provide new and additive information about CAD risk

that is independent of traditional risk factors, such as blood

cholesterol, to help physicians more effectively assess their

patients' risk. The test is conducted in less than 5 minutes with

results being immediately available.

About Pear Healthcare Solutions

Pear Healthcare Solutions is a privately held company specializing in

the development and implementation of programs to address the evolving

needs of pharmacists in their expanding role of providing healthcare

and disease management services. Pear Healthcare Solutions offers a

number of innovative medical devices and professional education

programs that help pharmacies connect with their patients, improving

their health and wellness. Pear provides distribution, training and

support/education services. For more information visit

About Miraculins Inc.

Miraculins is a medical diagnostic development company focused on

acquiring, developing and commercializing non-invasive tests for unmet

clinical needs. The Company's PreVu test is a revolutionary new

coronary artery disease risk assessment technology that measures

cholesterol levels in a patient's skin non-invasively, painlessly and

without the need for fasting. The PreVu Non-Invasive Skin Cholesterol

Point of Care (POC) Test technology has been cleared for sale by

Health Canada and CE-Marked in the European Union. PreVu has

previously been successfully test marketed in North America on a

limited basis. Miraculins' additional programs include a research use

only ELISA kit for the detection of PSP94; and a suite of biomarkers

to aid in the early detection of the devastating disease of pregnancy

known as preeclampsia. The Company's preeclampsia program is being

advanced in partnership with Alere, Inc. (NYSE:ALR) (formerly known as

Inverness Medical Innovations), one of the world's largest diagnostic


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute

forward-looking information within the meaning of applicable Canadian

provincial securities legislation (collectively, "forward-looking

statements"). These forward-looking statements relate to, among other

things, our objectives, goals, targets, strategies, intentions, plans,

beliefs, estimates and outlook, including, without limitation, our

anticipated future operating results, and can, in some cases, be

identified by the use of words such as "believe," "anticipate,"

"expect," "intend," "plan," "will," "may" and other similar

expressions. In addition, any statements that refer to expectations,

projections or other characterizations of future events or

circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on

information currently available to management. Certain material

factors or assumptions are applied in making forward-looking

statements, and actual results may differ materially from those

expressed or implied in such statements. Important factors that could

cause actual results to differ materially from these expectations

include, among other things: Miraculins' early stage of development,

lack of product revenues and history of operating losses,

uncertainties related to clinical trials and product development,

rapid technological change, uncertainties related to forecasts,

competition, potential product liability, additional financing

requirements and access to capital, unproven markets, supply of raw

materials, income tax matters, management of growth, partnerships for

development and commercialization of technology, effects of insurers'

willingness to pay for products, system failures, dependence on key

personnel, foreign currency risk, risks related to regulatory matters

and risks related to intellectual property and other risks detailed

from time to time in Miraculins' filings with Canadian securities

regulatory authorities, as well as Miraculins' ability to anticipate

and manage the risks associated with the foregoing. Additional

information about these factors and about the material factors or

assumptions underlying such forward-looking statements may be found in

the body of this news release. Miraculins cautions that the foregoing

list of important factors that may affect future results is not

exhaustive. When relying on Miraculins' forward-looking statements to

make decisions with respect to Miraculins investors and others should

carefully consider the foregoing factors and other uncertainties and

potential events.

These risks and uncertainties should be considered carefully and

prospective investors should not place undue reliance on the

forward-looking statements. Although the forward-looking statements

contained in this press release are based upon what management

believes to be reasonable assumptions, Miraculins cannot provide

assurance that actual results will be consistent with these

forward-looking statements. Miraculins undertakes no obligation to

update or revise any forward-looking statement.

PreVu@ is a registered trademark of Miraculins Inc. All Rights

Reserved. 2012.

Neither TSX Venture Exchange nor its Regulation Services Provider (as

that term is defined in the policies of the TSX Venture Exchange)

accepts responsibility for the adequacy or accuracy of this release.